Patient/carer group or patient expert statement

Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS.

Patients and patient advocates can provide a unique perspective on the technology, which is not typically available from the published literature.

To help you give your views, we have provided a template. The questions are there as prompts to guide you. You do not have to answer every question. Please do not exceed the 8-page limit.

About you
Your name: David Chandler
Name of your organisation (if applicable): Psoriatic Arthropathy Alliance
Are you (tick all that apply):
- $\int a$ patient with the condition for which NICE is considering this technology?
 a carer of a patient with the condition for which NICE is considering this technology?
 Jan employee of a patient organisation that represents patients with the condition for which NICE is considering the technology? If so, give your position in the organisation where appropriate (e.g. policy officer, trustee, member, etc)
- other? (please specify)

What do patients and/or carers consider to be the advantages and disadvantages of the technology for the condition?
 Advantages (a) Please list the specific aspect(s) of the condition that you expect the technology to help with. For each aspect you list please describe, if possible, what difference you expect the technology to make.
 (b) Please list any short-term and/or long-term benefits that patients expect to gain from using the technology. These might include the effect of the technology on: the course and/or outcome of the condition physical symptoms pain
 level of disability mental health quality of life (lifestyle, work, social functioning etc.) other quality of life issues not listed above other people (for example family, friends, employers) other issues not listed above.

What do patients and/or carers consider to be the advantages and disadvantages of the technology for the condition? (continued)

2. Disadvantages

Please list any problems with or concerns you have about the technology. Disadvantages might include:

- aspects of the condition that the technology cannot help with or might make it worse.
- difficulties in taking or using the technology
- side effects (please describe which side effects patients might be willing to accept or tolerate and which would be difficult to accept or tolerate)
- impact on others (for example family, friends, employers)
- financial impact on the patient and/or their family (for example cost of travel needed to access the technology, or the cost of paying a carer).

3. Are there differences in opinion between patients about the usefulness or otherwise of this technology? If so, please describe them.

4. Are there any groups of patients who might benefit **more** from the technology than others? Are there any groups of patients who might benefit **less** from the technology than others?

Patient Organisation Submission Template Single Technology Appraisal of Infliximab for the treatment of psoriasis

available treatments or
echnology compares with with existing
Iternatives if any) used in the UK.
ay advantages for patients over other em. Advantages might include: e condition er than injection) (for example at home rather than in and number of problems, frequency,
hy disadvantages for patients use describe them. Disadvantages condition rather than tablets) (for example in hospital rather than at umber of problems, how often, for how

1	
	Research evidence on patient or carer views of the technology
	If you are familiar with the evidence base for the technology, please comment on whether patients' experience of using the technology as part of their routine NHS care reflects that observed under clinical trial conditions.
	Are there any adverse effects that were not apparent in the clinical trials but have come to light since, during routine NHS care?
	Are you aware of any research carried out on patient or carer views of the condition or existing treatments that is relevant to an appraisal of this technology? If yes, please provide references to the relevant studies.

Availability of this technology to patients in the NHS
What key differences, if any, would it make to patients and/or carers if this technology was made available on the NHS?
What implications would it have for patients and/or carers if the technology was not made available to patients on the NHS?
Are there groups of patients that have difficulties using the technology?

Other Issues

Please include here any other issues you would like the Appraisal Committee to consider when appraising this technology.

Patient Organisation Submission Template Single Technology Appraisal of Infliximab for the treatment of psoriasis